Milestone Pharmaceuticals Inc. (MIST) Stock Analysis and Metrics

Milestone Pharmaceuticals

NASDAQ: MIST

$1.15 ▼ -0.05 (-3.75%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap156.34 Mn

Div. Yield0.00

Total Debt (Qtr)58.19 Mn

Add ratio to table…

About

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. The firm concentrates on creating therapies that address unmet needs in episodic cardiac arrhythmias. Its lead product CARDAMYST etripamil nasal spray has received FDA approval for the treatment of paroxysmal supraventricular tachycardia in adult patients. Beyond this approved indication the company is advancing etripamil for the management of atrial fibrillation with rapid ventricular rate commonly referred to as AFib RVR. The organization was founded in 2003 and maintains headquarters in Montreal Canada with a subsidiary in Charlotte North Carolina. Its research and development efforts are directed toward optimizing the pharmacokinetic profile of calcium channel blockers to achieve rapid onset and short duration of action.

Milestone Pharmaceuticals generates revenue principally from the sale of CARDAMYST etripamil nasal spray to wholesalers who then distribute the product to retail pharmacies across the United States. The company launched the product in the first quarter of 2026 and has deployed a dedicated sales force of approximately sixty representatives targeting cardiology and high volume primary care practices. Revenue is recognized when prescriptions are filled and the drug is dispensed to patients through the retail channel. In addition to product sales the firm may receive milestone payments royalties or profit sharing from collaboration partners seeking to commercialize etripamil in territories outside the United States. The organization is also investing in market access initiatives to secure favorable reimbursement from private insurers and government payors which is essential for sustaining long term sales growth.

The market for acute treatment of PSVT has historically depended on intravenous administration of adenosine verapamil or diltiazem in emergency department settings. These conventional options require patients to seek care in a medical facility and are associated with discomfort and prolonged visits. Milestone Pharmaceuticals differentiates itself by offering the first FDA approved nasal spray that enables patients to self administer therapy at the onset of symptoms. This innovation addresses a significant unmet need for a convenient rapid acting alternative that can be used outside of a hospital. The company estimates that more than two million Americans live with PSVT and that a substantial portion of this population experiences recurrent episodes that drive healthcare utilization. Competitors in the arena include established drug manufacturers that provide intravenous antiarrhythmic agents and emerging biotech firms developing novel molecules such as InRhythm with flecainide Acesion Pharma with an SK channel inhibitor and Rapiblyk with landiolol. Milestone's competitive advantages stem from the rapid onset of action of etripamil its convenient nasal delivery and the potential to reduce reliance on emergency department care thereby lowering overall treatment costs for patients and payors.

The primary customers for Milestone Pharmaceuticals are patients diagnosed with paroxysmal supraventricular tachycardia who seek rapid relief of symptomatic episodes. A growing segment of the customer base consists of individuals experiencing atrial fibrillation with rapid ventricular rate who may benefit from self administered rate control therapy. The company also serves healthcare providers such as cardiologists electrophysiologists and internal medicine physicians who prescribe CARDAMYST to appropriate patients. Pharmacies and drug wholesalers form an essential part of the distribution network ensuring the medication reaches the point of dispense. Finally private health insurers Medicare Medicaid and managed care organizations influence reimbursement and thus constitute important stakeholders in the commercial ecosystem.

Investment Thesis

▲ Bull case

Milestone Pharmaceuticals (MIST) is positioned to leverage its early commercial traction in the PSVT market as a springboard for substantial growth in the larger AFib-RVR indication, which remains significantly underappreciated by investors. The successful launch of CARDAMYST has demonstrated strong initial adoption, with approximately 600 prescriptions written by over 400 unique prescribers in the first partial quarter, reflecting broad engagement across cardiologists (50%), electrophysiologists (25%), and advanced practice providers (25%). This early prescriber diversity, particularly the meaningful uptake among electrophysiologists who are key opinion leaders in arrhythmia management, signals robust clinical validation that extends beyond PSVT into the AFib-RVR space where the same mechanism of action is being tested in the ReVeRa-301 trial. The fact that many prescriptions were generated after only one or two sales rep interactions underscores the compelling nature of the drug’s value proposition—safety, ease of self-administration, and rapid symptom relief—suggesting that as commercial efforts scale and coverage expands, prescribing depth per physician will increase meaningfully. Management’s strategy to avoid over-promoting initially to prevent physician frustration due to coverage gaps has created a latent demand that is poised to unlock as formulary access improves, particularly with the Express Scripts National Formulary win already securing coverage for approximately 25% of commercially insured lives. This early payer validation, achieved faster than anticipated, reduces a major commercial risk and provides a template for negotiating similar terms with other large PBMs and health plans, setting the stage for accelerated net prescription growth in subsequent quarters. Furthermore, the initiation of the Phase III ReVeRa-301 trial for AFib-RVR represents a transformative opportunity that the market is not fully pricing in; with an estimated 10 million Americans living with atrial fibrillation and a significant subset experiencing symptomatic rapid ventricular rate episodes, the addressable market for etripamil in this indication dwarfs the PSVT opportunity. The trial’s design—mirroring the successful PSVT program with patient self-administration, identical dosing, and event-driven endpoints—leverages existing clinical infrastructure and operational expertise, lowering execution risk while increasing the probability of success. Given the company’s strong cash position of approximately $184 million, funded in part by the $75 million RTW royalty agreement and ATM proceeds, MIST has sufficient runway to support both the CARDAMYST launch through 2027 and the full execution of the ReVeRa-301 trial, with first patient enrollment expected in the second half of 2026. This financial flexibility, combined with de-risked commercial progress and a pivotal pipeline milestone on the horizon, creates a compelling scenario where the market is underestimating the dual-engine growth potential of near-term commercial execution in PSVT and long-term pipeline validation in AFib-RVR.

Milestone Pharmaceuticals (MIST) is positioned to leverage its early commercial traction in the PSVT market as a springboard for substantial growth in the larger AFib-RVR indication, which remains significantly underappreciated by investors. The successful launch of CARDAMYST has demonstrated strong initial adoption, with approximately 600 prescriptions written by over 400 unique prescribers in the first partial quarter, reflecting broad engagement across cardiologists (50%), electrophysiologists (25%), and advanced practice providers (25%). This early prescriber diversity, particularly the meaningful uptake among electrophysiologists who are key opinion leaders in arrhythmia management, signals robust clinical validation that extends beyond PSVT into the AFib-RVR space where the same mechanism of action is being tested in the ReVeRa-301 trial. The fact that many prescriptions were generated after only one or two sales rep interactions underscores the compelling nature of the drug’s value proposition—safety, ease of self-administration, and rapid symptom relief—suggesting that as commercial efforts scale and coverage expands, prescribing depth per physician will increase meaningfully. Management’s strategy to avoid over-promoting initially to prevent physician frustration due to coverage gaps has created a latent demand that is poised to unlock as formulary access improves, particularly with the Express Scripts National Formulary win already securing coverage for approximately 25% of commercially insured lives. This early payer validation, achieved faster than anticipated, reduces a major commercial risk and provides a template for negotiating similar terms with other large PBMs and health plans, setting the stage for accelerated net prescription growth in subsequent quarters. Furthermore, the initiation of the Phase III ReVeRa-301 trial for AFib-RVR represents a transformative opportunity that the market is not fully pricing in; with an estimated 10 million Americans living with atrial fibrillation and a significant subset experiencing symptomatic rapid ventricular rate episodes, the addressable market for etripamil in this indication dwarfs the PSVT opportunity. The trial’s design—mirroring the successful PSVT program with patient self-administration, identical dosing, and event-driven endpoints—leverages existing clinical infrastructure and operational expertise, lowering execution risk while increasing the probability of success. Given the company’s strong cash position of approximately $184 million, funded in part by the $75 million RTW royalty agreement and ATM proceeds, MIST has sufficient runway to support both the CARDAMYST launch through 2027 and the full execution of the ReVeRa-301 trial, with first patient enrollment expected in the second half of 2026. This financial flexibility, combined with de-risked commercial progress and a pivotal pipeline milestone on the horizon, creates a compelling scenario where the market is underestimating the dual-engine growth potential of near-term commercial execution in PSVT and long-term pipeline validation in AFib-RVR.

▼ Bear case

Milestone Pharmaceuticals (MIST) faces substantial near-term headwinds that the market may be overlooking, despite the optimistic narrative around early CARDAMYST launch metrics. While the company reported approximately 600 prescriptions and over 400 unique prescribers in the initial launch period, these figures must be contextualized against the steep commercialization costs incurred—$15.8 million in commercial expense during Q1 2026, up from $10.4 million in the prior year period—resulting in a negligible $0.2 million in net product revenue. This implies an exceptionally high cost per prescription, raising serious concerns about the scalability and efficiency of the current go-to-market strategy, especially as the sales force of 60 representatives has only engaged roughly one-third of the 10,000-target provider base to date. The reliance on minimal rep interactions (one or two) to drive initial prescriptions, while indicative of strong product appeal, may not be sustainable for generating repeat usage or deeper penetration, particularly if broader coverage does not materialize quickly. Furthermore, the emphasis on "quality coverage" from Express Scripts—defined as minimal prior authorization burden and refill flexibility—remains largely aspirational, as management admitted they cannot guarantee the extent to which such favorable terms will apply across the covered lives, introducing uncertainty about real-world access and patient persistence. The company’s strategy of avoiding free drug distribution to demonstrate organic payer demand, while logically sound, may be inadvertently limiting uptake, as patients facing administrative hurdles could abandon the prescription process entirely, especially in a therapy where episodes are infrequent and acute. This dynamic is compounded by the fact that approximately half of the target patient population relies on Medicare, a segment where coverage decisions lag commercial payers and where MIST has not yet secured any formulary placements, leaving a significant portion of the addressable market untapped in the near term. On the clinical front, while the initiation of the ReVeRa-301 Phase III trial for AFib-RVR is a necessary step, it remains an early-stage endeavor with enrollment not expected to begin until the second half of 2026 and a projected timeline of approximately two years to completion—meaning any potential revenue contribution from this indication is at least three to four years away. During this extended window, the company will continue to incur significant operating cash burn, which was $23.7 million in Q1 2026, and must rely on its current cash balance of $184 million to fund both commercial operations and trial execution. Although this provides runway into the second half of 2027, the combination of slowing prescription momentum without accelerated payer access, limited differentiation in a crowded arrhythmia treatment landscape, and the opportunity cost of capital tied up in a long-duration clinical program increases the risk that MIST fails to achieve meaningful scale before needing additional financing, potentially under less favorable terms. The market may be overestimating the durability of early launch enthusiasm and underestimating the structural challenges of converting physician interest into sustained, reimbursed prescribing patterns at scale, particularly without broader and more rapid formulary expansion beyond the initial Express Scripts win.

Milestone Pharmaceuticals (MIST) faces substantial near-term headwinds that the market may be overlooking, despite the optimistic narrative around early CARDAMYST launch metrics. While the company reported approximately 600 prescriptions and over 400 unique prescribers in the initial launch period, these figures must be contextualized against the steep commercialization costs incurred—$15.8 million in commercial expense during Q1 2026, up from $10.4 million in the prior year period—resulting in a negligible $0.2 million in net product revenue. This implies an exceptionally high cost per prescription, raising serious concerns about the scalability and efficiency of the current go-to-market strategy, especially as the sales force of 60 representatives has only engaged roughly one-third of the 10,000-target provider base to date. The reliance on minimal rep interactions (one or two) to drive initial prescriptions, while indicative of strong product appeal, may not be sustainable for generating repeat usage or deeper penetration, particularly if broader coverage does not materialize quickly. Furthermore, the emphasis on "quality coverage" from Express Scripts—defined as minimal prior authorization burden and refill flexibility—remains largely aspirational, as management admitted they cannot guarantee the extent to which such favorable terms will apply across the covered lives, introducing uncertainty about real-world access and patient persistence. The company’s strategy of avoiding free drug distribution to demonstrate organic payer demand, while logically sound, may be inadvertently limiting uptake, as patients facing administrative hurdles could abandon the prescription process entirely, especially in a therapy where episodes are infrequent and acute. This dynamic is compounded by the fact that approximately half of the target patient population relies on Medicare, a segment where coverage decisions lag commercial payers and where MIST has not yet secured any formulary placements, leaving a significant portion of the addressable market untapped in the near term. On the clinical front, while the initiation of the ReVeRa-301 Phase III trial for AFib-RVR is a necessary step, it remains an early-stage endeavor with enrollment not expected to begin until the second half of 2026 and a projected timeline of approximately two years to completion—meaning any potential revenue contribution from this indication is at least three to four years away. During this extended window, the company will continue to incur significant operating cash burn, which was $23.7 million in Q1 2026, and must rely on its current cash balance of $184 million to fund both commercial operations and trial execution. Although this provides runway into the second half of 2027, the combination of slowing prescription momentum without accelerated payer access, limited differentiation in a crowded arrhythmia treatment landscape, and the opportunity cost of capital tied up in a long-duration clinical program increases the risk that MIST fails to achieve meaningful scale before needing additional financing, potentially under less favorable terms. The market may be overestimating the durability of early launch enthusiasm and underestimating the structural challenges of converting physician interest into sustained, reimbursed prescribing patterns at scale, particularly without broader and more rapid formulary expansion beyond the initial Express Scripts win.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	68,785.72 Bn	-32.10 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,895.57 Bn	0.00 Bn	56,599.40	0.11 Bn
3	ONC	BeOne Medicines Ltd.	471.35 Bn	0.00 Bn	82.13	0.96 Bn
4	NCNA	NuCana plc	279.75 Bn	0.00 Bn	-	-
5	VRTX	Vertex Pharmaceuticals Inc / Ma	120.24 Bn	0.00 Bn	9.84	-
6	REGN	Regeneron Pharmaceuticals, Inc.	67.80 Bn	0.00 Bn	4.54	1.99 Bn
7	BLTE	Belite Bio, Inc	62.51 Bn	367.72 Bn	-	-
8	ARGX	Argenx Se	57.38 Bn	0.00 Bn	12.31	-

Research Tools

Developers

About

Investment Thesis

Counterparty Name Breakdown of Revenue (2021)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Counterparty Name Breakdown of Revenue (2021)

Peer Comparison

Create an account

Sign In

Reset Password